COMMUNIQUÉS West-GlobeNewswire

HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Savolitinib for the treatment of Gastric Cancer Patients with MET Amplification
30/12/2025
— NDA supported by positive Phase II registration study data in Chinese patients; follows Breakthrough Therapy Designation granted in 2023 — — Savolitinib has the potential to become the first selective MET inhibitor in [...]
Kestra Medical Technologies to Present at the 44th Annual J.P. Morgan Healthcare Conference
30/12/2025
KIRKLAND, Wash., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, is scheduled to present at the 44th Annual J.P. Morgan [...]
Best Zepbound Alternative for 2026? FDA Regulatory Timeline Reshapes Telehealth Tirzepatide Access as SkinnyRx Platform Lists Compounded Options
30/12/2025
Industry analysis examines published SURMOUNT clinical trial data, evolving FDA compounding guidance, and telehealth access pathways using SkinnyRx as a platform reference based on publicly available disclosures. [...]
IvesMD Opens New Beverly Hills Headquarters, Expands Team to Meet Growing Demand for Inclusive Aesthetic and Gender-Affirming Care
30/12/2025
Plastic Surgery Practice, IvesMD, launches its next chapter with award-winning space designed by Maria Park Design BEVERLY HILLS, Calif., Dec. 29, 2025 (GLOBE NEWSWIRE) -- IvesMD , founded by Dr. Graham Ives M.D. and [...]
Best Weight Loss Pills for 2026? FDA Approves First Oral GLP-1 as Patients Evaluate Wegovy, Zepbound, and Telehealth Access Pathways
30/12/2025
Industry Analysis Examines How FDA's First Oral GLP-1 Approval, Published Clinical Trial Data, and Evolving Telehealth Access Shape Patient Choices as MEDVi Lists Compounded GLP-1 Programs Starting at $179 Newark, DE, [...]
Mesoblast Retires Senior Debt with Non-Dilutive, Lower Cost, Five-Year Credit Line
30/12/2025
Mesoblast has option to draw down up to US$125 million by June 30, 2026 New facility does not encumber any of Mesoblast's material assets or intellectual property NEW YORK, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Mesoblast [...]
Changes in company's own shares
29/12/2025
Attached is a filing with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding changes in company's own shares. Attachment Alvotech Own Shares Notification 29 Dec 2025
CapsoVision Announces 510(k) Submission for the Addition of AI-Assisted Reading Module in CapsoCam Plus®
29/12/2025
Company Preparing to Commence Commercialization Following U.S. FDA 510(k) Clearance SARATOGA, Calif., Dec. 29, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company [...]
Nyxoah Fera une Présentation lors de la 44ème Conférence Annuelle J.P. Morgan Healthcare
29/12/2025
Nyxoah Fera une Présentation lors de la 44 ème Conférence Annuelle J.P. Morgan Healthcare Mont-Saint-Guibert, Belgique – 29 décembre 2025, 22h05 CET / 16h05 ET – Nyxoah SA (Euronext Bruxelles/Nasdaq : NYXH) (« Nyxoah » [...]
Nyxoah to Present at the 44th Annual J.P. Morgan Healthcare Conference
29/12/2025
Nyxoah to Present at the 44 th Annual J.P. Morgan Healthcare Conference Mont-Saint-Guibert, Belgium – December 29, 2025, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), [...]
CooperCompanies to Present at the J.P. Morgan Healthcare Conference
29/12/2025
SAN RAMON, Calif., Dec. 29, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading medical device company, announced today it will participate at the J.P. Morgan Healthcare Conference on Wednesday, January 14 [...]
IMUNON 2025, A TRANSFORMATIVE YEAR OF SIGNIFICANT CLINICAL ADVANCES, LOOKING AHEAD TO 2026
29/12/2025
Enrollment in the Pivotal Phase 3 OVATION 3 Study Advances Company Toward Future BLA Filing New Data from MRD Study Reinforces IMNN-001's Promise as a Potential Breakthrough Immunotherapy LAWRENCEVILLE, N.J., Dec. 29, [...]
60 Degrees Pharmaceuticals Announces Detection of Babesia Infection in 24 Percent of Patients Presenting with Chronic Fatigue in Peer-Reviewed, Sponsored Study at NC State
29/12/2025
Further validates continuation of the B-FREE Study to evaluate the efficacy and safety of ARAKODA ® ( tafenoquine ) for treatment of chronic babesiosis Data support theory among specialists that Babesia infection may [...]
Genmab Portfolio Prioritization Update
29/12/2025
Company Announcement Genmab to discontinue clinical development of acasunlimab following a portfolio review Decision reflects prioritization of higher ‑ impact opportunities across Genmab’s late ‑ stage pipeline and [...]
MEDIROM Partners with World on Technology Envisioned by Sam Altman and Alex Blania: Deploying “Proof of Human” Infrastructure throughout Japan
29/12/2025
TOKYO, Dec. 29, 2025 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (Headquarters:Minato-ku, Tokyo; CEO: Kouji Eguchi; NASDAQ: MRM, MEDIROM or the “Company”), a diversified healthcare company, collaborating [...]
The Better Brain Company’s Dementia Prevention Expert Dr. Clint Steele Releases “101 Brain Hacks To Prevent and Even Reverse Dementia”
29/12/2025
Portland, Maine, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Most people believe dementia is a life sentence. Dr. Clint Steele once believed that, too, until a moment in his practice changed everything. Today, the #1 best-selling [...]
Branded Legacy, Inc. Announces Successful Retirement of Legacy Convertible Debt as New Management Focuses on Balance Sheet Optimization and OTC Yield Sign Removal
29/12/2025
VANCOUVER, British Columbia, Dec. 29, 2025 (GLOBE NEWSWIRE) -- via IBN -- Branded Legacy, Inc. (OTC: BLEG ) under the leadership of Dr. Jamie Forrest, PhD, MPH, today announced the successful elimination of [...]
QHSLab, Inc. (OTCQB:USAQ) Completes $500K Private Placement, Enters 2026 With Clean Capital Structure
29/12/2025
With legacy overhang removed and new capital secured, management shifts focus from balance-sheet repair to disciplined growth execution. West Palm Beach, FL, Dec. 29, 2025 (GLOBE NEWSWIRE) -- QHSLab Inc. (the “Company [...]
Ultragenyx Announces Phase 3 Orbit and Cosmic Results for Setrusumab (UX143) in Osteogenesis Imperfecta
29/12/2025
Neither study achieved its primary endpoint of reduction in annualized clinical fracture rate compared to placebo (Orbit) or bisphosphonates (Cosmic) Both studies achieved the secondary endpoint of improvements in bone [...]

Pages